Bli medlem
Bli medlem

Du är här


Nordic Nanovector: Title: Extraordinary General Meeting in Nordic Nanovector

Date: 19.06.2014        Press Release no: 17/2014

Reference is made to the announcement made on 18 June 2014 regarding
the successful completion of the Company's MUSD 41.6 (NOK 250
million) pre-IPO private placement.

The Board of Directors has resolved to call for an Extraordinary
General Meeting to be held on 27 June 2014 at 15:00 (CET) in the
Company's offices at Kjelsåsveien 168 B, 4th floor, Oslo to approve
the private placement, a MUSD 8.3 (NOK 50 million) subsequent share
issue directed at those shareholders who do not participate in the
private placement, increase in the authorization to the Board to
issue new shares, changes to the articles of association and the
election of a deputy Board member.

Attached is the notice of the Extraordinary General Meeting. The
notice will be sent to the Nordic Nanovector shareholders today.

Jan A. Alfheim, CEO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 46 44 00 45
Fax: ( 47) 22 58 00 07

Tone Kvåle, CFO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 91 51 95 76
Fax: ( 47) 22 58 00 07

About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009.
The company is based in Norway and has offices and laboratories in
Oslo. The company is developing novel innovative anticancer
radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other
hematological malignancies.

About Betalutin
Betalutin™, is a pharmaceutical product candidate consisting of a
radionuclide conjugated to a tumor seeking carrier/antibody, which
can be used for irradiation of malignant metastasized tumors with
minimal damage to nearby healthy normal tissue. This technology aims
to prolong and improve the quality of life of people who suffer from
non-Hodgkin Lymphoma (NHL).


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.